



### **ANDREW FEIN LAUNCHES COVERAGE AT H.C. WAINWRIGHT & CO., LLC**

**NEW YORK, NY** – H.C. Wainwright & Co., LLC, today announced that Senior Biotechnology Analyst, Andrew Fein, has launched coverage in the biotechnology sector at the firm. Fein is also a Managing Director at H.C. Wainwright & Co., LLC.

Fein said: “I am very happy to be out publishing research once again. We hope to establish a reputation at H.C. Wainwright for thorough, well diligenced research across all market caps.”

Fein initiated coverage on the following companies

- 1) United Therapeutics (UTHR), Buy, \$85 price target
- 2) Vertex (VRTX), Buy, \$100 price target
- 3) Amarin (AMRN), Neutral, \$6 price target
- 4) Kamada (KMDA), Buy, \$17 price target
- 5) Synthetic Biologics (SYN), Buy, \$4 price target
- 6) NeoStem (NBS), Buy, \$2 price target
- 7) Cel-Sci (CVM), Buy, \$1 price target

Contact:

***H.C. Wainwright & Co., LLC***

430 Park Avenue, 4th Floor  
New York, New York 10022  
212-356-0500

[info@hcwco.com](mailto:info@hcwco.com)

[www.hcwco.com](http://www.hcwco.com)